• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Pain management overview 2013
 

Pain management overview 2013

on

  • 3,838 views

 

Statistics

Views

Total Views
3,838
Views on SlideShare
2,909
Embed Views
929

Actions

Likes
5
Downloads
0
Comments
3

2 Embeds 929

http://libguides.mskcc.org 926
http://study.myllps.com 3

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel

13 of 3 previous next Post a comment

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Pain management overview 2013 Pain management overview 2013 Presentation Transcript

    • Y V O N A G R I F F O , M DP A I N & P A L L I A T I V E C A R E S E R V I C EM E M O R I A L S L O A N K E T T E R I N G C A N C E RC E N T E RPAIN MANAGEMENTThe following material is intended for MSKCC internal medicine housestaff teachingpurposes only. The slides were updated for the LibGuide in 2012-2013.
    • 2The InternationalAssociation fortheStudy of Pain:An unpleasantsensory oremotionalexperienceassociated withactual or potentialtissue damage ordescribed in termsof such damage
    • BASIC APPROACH1. ETIOLOGY of PAIN2. CLASSIFICATION of PAIN3. ASSESEMENT of PAIN4. TREATMENT of PAIN
    • ETIOLOGY PAIN CAUSED BY CANCER Infiltration of Bone, Viscera, Soft tissue, Muscles Infiltration of Spinal Cord, Roots ,Plexus or PeripheralNerves Occlusion of Blood Vessels PAIN AS SEQUELAE OF CANCERTREATMENT PAIN DUE TO FRAILTY PAIN UNRELATED TO CANCER
    • ETIOLOGY-Treatment relatedPOST-SURGICAL - Phantom Pain- Neuroma- Adhesions- Post-Thoracotomy, MastectomyCHEMOTHERAPY -Peripheral Neuropathy-MucositisRADIOTHERAPY -Radiation Dermatitis-Radiation Neuritis
    • Mixed TypeCaused by acombination of bothprimary injury orsecondary effectsCLASSIFICATION of PAINNociceptivePainCaused by activity inneural pathways inresponse to potentiallytissue-damaging stimuliNeuropathicPainInitiated or caused byprimary lesion ordysfunction in thenervous systemPostoperativepainMechanicallow back painSickle cellcrisisArthritisPostherpeticneuralgiaNeuropathiclow back painCRPS*Sports/exerciseinjuries*Complex regional pain syndromeCentral post-stroke pain, spineTrigeminalneuralgiaDistalpolyneuropathy(eg, diabetic, HIV)
    • CANCER PAIN INITIAL ASSESMENT and DIAGNOSIS ofUnderlying cause TREATMENT OF ACUTE UNDERLYING CAUSE SPECIFIC ANTI-TUMOR THERAPY-Surgery-Radiation-Chemotherapy PAIN MANAGEMENT-ANALGESICSWHO LADDER Step 1-3
    • CLINICAL ASSESSMENT OF PAIN8Believe the patient’s self-report of painTake a careful history—ONSET (temporal pattern) of pain—LOCATION site of pain/widespread or localized/uni-bilateral—DURATION of pain /constant or incidental/—CHARACTER/quality and intensity of pain/—AGGRAVATING/RELIEVING factors—RESPONSE to analgesics—DEGREE of intensity and interference with patient’s life—ASSOCIATED signs and symptoms
    • ASSESSMENT of PAIN INTENSITYNo Mild Moderate Severe Very Worstpain pain pain pain severe possiblepain painVerbal Pain Intensity ScaleNopainVisual Analog ScaleFaces Scale0 1 2 3 4 50–10 Numeric Pain Intensity ScaleNo Moderate Worstpain pain possible pain0 1 2 3 4 5 6 7 8 9 10Worstpossiblepain19
    • WHO –3 Steps ANALGESICS LADDER For mild pain, use non-opioid first When pain persists or increases, add an opioid If pain becomes more severe, increase the opioidpotency or dose Schedule doses on around-the-clock basis, withadditional PRN doses -rescues
    • ADJUVANT ANALGESICS Anticonvulsants Antidepressants Corticosteroids Neuroleptics Anxiolytics Muscle relaxants Anesthetics Antispasmodics
    • BASIC PAIN MANAGEMENT Believe Pt’s self report Assess factors affecting Pt’s pain report (medical,psychological, spiritual, functional) Titrate analgesics to effectiveness and tolerance ofside effects If on ATC opioid must have PRN Treat Opioids side effects (bowel regimen)
    • STEP 1- WHO ANALGESICS14NON-OPIOID ANALGESICSACETAMINOPHENNASIDS -(COX -2 INHIBITORS,ASA, SALICYLIC ACIDDERIVATIVES)Benefits:NO TOLERANCE or PHYSICAL DEPENDENCEADDITIVE ANALGESIA when COMBINDED with an OPIOIDCaution:CEILIING EFFECT for ANALGESIARISKS RELATED to PLATELET DYSFUNCTION, GASTRICULCERATION and GI BLEEDING, CARDIOVASCULAR EVENTS,HTN, RENAL INSUFFICIENCY or LIVER TOXICITY
    • STEP 2- WHO ANALGESICS15WEAK OPIOIDSCODEINEHYDROCODONEOXYCODONE –(in combination with a non-opioid)TRAMADOL (mu-agonist, norepinephrineand serotonin reuptake inhibitor)TAPENTADOL (mu-agonist, norepinephrinereuptake inhibitor)
    • STEP 3 – WHO ANALGESICSSTRONG OPIOIDSMORPHINEHYDROMORPHONEFENTANYLOXYCODONEMETHADONELEVORPHANOLBUPRENORPHINEOXYMORPHONEMEPERIDINE
    • CHOOSING THE OPIOID ANALGESIC17Patient sensitivity and allergyPrior opioid exposureCurrent intensity of pain or pain crisisPain pathophysiology (nociceptive vs neuropathic)Available route of administrationRequirements for rescue medicationsMetabolic factorsDrug interactionsCost/availability and formulary preparationsStreet value
    • ROUTES of OPIOID ADMINISTRATION ORAL -tablets, elixirs RECTAL-suppository TRANSDERMAL, TRANSBUCCAL SUBCUTANEOUS INTRAVENOUS bolus, continuous infusion, PCA EPIDURAL INTRATHECAL
    • ALGORITHM for OPIOID THERAPYPatientSelectionInitial PatientAssessmentTrial of OpioidTherapyAlternatives toOpioid TherapyPatientReassessmentExit StrategyConversion toLong-actingOpioidOpioid RotationContinueOpioid Therapy Used with permission of Nathaniel P. Katz, MD7
    • MONITORING OPIOID THERAPY20Continual monitoring and follow-ups areessential to good opioid analgesic therapy –during the trial and throughout chronic therapyCRITICAL OUTCOMES = “4 A’s of Pain” Analgesia Adverse effects Activities of daily living Aberrant opioid-related behaviorAdjust and Manage therapy based onoutcomesDocument critical outcomes
    • 21Short acting Opioids = (immediate release preparations)– Morphine (MSIR ®, Roxanol ™, rectal suppositories– Codeine (Tylenol with codeine, Soma)– Hydrocodone (Vicodin ®, Zydone ® Lortab ®,Vicoprofen ®, Norco®)– Oxycodone (Roxicodone, Oxy IR ®, OxyFAST, Percocet®, Percodan ®, Tylox ®)– Hydromorphone (Dilaudid ®)– Oxymorphone (Opana IR)– Fentanyl (Actiq ®, Fentora ®,Onsolis)CATEGORIES OF OPIOID ANALGESICS
    • CATEGORIES OF OPIOID ANALGESICSLONG – ACTING OPIOIDS – EXTENDED RELEASEPREPARATIONS Morphine sustained – release (MS Contin, Avinza, Kadian,Oramorph) Oxycodone sustained – release (OxyContin) Oxymorphone – sustained release (Opana ER) Fentanyl – transdermal patches (Duragesic) Hydromorphone –(Exalgo)LONG – HALF LIFE OPIOIDS Methadone Buprenorphine Levorphanol
    • 23“GOLD STANDARD” – FOR TREATMENT ofMODERATE TO SEVERE PAIN”Full mu-receptor agonistBioavailability – 30% (PO: IV dose is 3:1)Easily available in wide range of preparations– Immediate and sustained release– Oral tablets, elixir, suspension, capsules– Rectal suppositories– Parenteral (IV, IM, SC, epidural, intrathecal)Most widely used opioid analgesicCAVEAT !!! – BID/TID medication– Active morphine metabolitesMORPHINE-6-GLUCURONIDEMORPHINE-3-GLUCURONIDEMORPHINE
    • 24Semisynthetic derivative of thebaineMost utilized opioid worldwideFull mu-receptor agonist, Kappa receptor agonist ??Bioavailability – 50%Oxycodone : morphine dose ration 1: 1.5-2IR and ER preparations, oral only(tablets or elixir)Sustained release preparation OXYCONTIN has 2phase release (immediate and extended in the samepill)OXYCODONE
    • FENTANYL25Full- mu receptor agonistHigh potency, short duration of action, rapid onset of actionLipophilic – ideal drug for transdermal and transmucosaladministrationbioavailability – 50%Parenteral, transdermal and transmucosal preparations25 mcg/hour transdermal Fentanyl patch = 1mg/1 hour IV MorphineTransdermal Fentanyl patch takes 12 hours to reach analgesic bloodlevels on initiation (6 – 18h)90 – 95% of transdermal Fentanyl reaches systemic circulation asunchanged FentanylConvenient to use (3 – day drug reservoir)Ideal for children and uncooperative/impaired adults
    • FENTANYL PATCH24-hour Oral Morphine Initial Fentanyl dose30-59 mg 12 mcg60-134 mg 25 mcg135-224 mg 50 mcg225-314 mg 75 mcg315-404 mg 100 mcg
    • ACTIQ, FENTORA, SUBSYS,ABSTRAL Transbuccal Fentanyl -No directcorrelation with TD Fentanyl dose !!! NEVER use for opioid naïve patient !!! Keep away from children, pets Restricted distribution-TIRF-REMS
    • 30Semisynthetic opioid, hydrogenated ketone analog ofmorphineFull, potent – mu – receptor agonistAvailable for oral, parenteral and rectal use PO:IVdose is 5:1Oral hydromorphone : morphine dose ration is 1: 4Parenteral hydromorphone : morphine dose ratio is1:7Short duration of action : 3-4 hoursHYDROMORPHONE
    • 31Synthetic opioid - mu- receptor agonist- NMDA receptor antagonist- serotonin reuptake inhibitorUnique pharmacology - variable and long half-life (8 – 80 hours)- steady-state plasma concentration up to 10 days- potency greater then expectedGood oral bioavailability – 60 – 95% PO:IV dose is 2:1Inexpensive and effective – oral( tablets or elixir) or parenteralBut requires special knowledge- how to initiate and titrate the dose- monitor for cardiac toxicity (QT prolongation )No active metabolites ! Clearance not influenced by hepatic or renalimpairmentMETHADONE
    • METHADONE32ACUTE USE: 1 MG IV MORPHINE = 1 MG IVMETHADONECHRONIC USE: 10 MG IV MORPHINE = 1MG IVMETHADONE30 – 90 mg daily PO Morphine 4 : 190 – 300 mg daily PO Morphine 6-8 : 1>300 mg daily PO Morphine 10-12 : 11960-s – in single dose studies morphine and methadonedoses are equal (Raymond Houde, Equianalgesicconversion tables)
    • OPIOID EQUIANALGESIC DOSESOpioid parenteral oral conversion duration(mg) (mg) (IV to PO) (hours)Morphine 10 30 3 3 - 4Methadone 10 20 2 4 - 8Hydromorphone 1.5 7.5 5 2 - 3Meperidine 75 300 4 2 - 3Levorphanol 2 4 2 4- 6Oxycodone - 20 - 3 - 5Oxymorphone 1 5 5 3 - 4Fentanyl 0.25 - 1 1- 2
    • OPIOID CONVERSIONS Calculate 24 hrs IV or PO requirement Multiply by IV or ORAL conversion factor Divide in multiple dosages or hourly rate dependingon medication to be used If using SR preparation, add 10-15% of 24 hrs dosein IR form for breakthrough pain PRN
    • OPIOID CONVERSION Example: Opioid equianalgesic values for:Morphine 10 mg IV= morphine 30 mg PO=hydromorphone 1.5 mg IV = hydromorphone 7.5 PO=Fentanyl 250 mcg IV = Methadone 1mg IV Example: Same drug, changed routeChange 90 mg q12 MS Contin PO to IV continuousinfusionCalculate 24-h current dose: 180 mg MS/24 hLook up equianalgesic ratio: PO/IV= 3Calculated new dose using ratios: 180/3=60 mg IV/24 hours =2.5 mg/h continuous infusion61
    • 36OPIOID THERAPYASSESMENTANALGESIA+ - -ADVERSEEFFECTS - + +   -CONTINUECURRENTOPIOIDINCREASEDOSE OFOPIOIDIMPROVEMANAGEMENTOF SIDE EFFECTSOPIOIDROTATION+
    • OPIOID SIDE EFFECTS37COMMON– CONSTIPATION– NAUSEA and VOMITING– COGNITIVE IMPAIRMENT• sedation• confusion• hallucinations• agitation/myoclonus– MIOSIS– RESPIRATORY DEPR.– COUGH SUPPRESSIONLESS COMMON– URINARY RETENTION– ENDOCRINEDYSFUNCTION– ITCHING (HISTAMINERELEASE)– SWEATING– HEADACHE– DELIRUM– BILIARY SPASM/GASTRIC STASIS– DRY MOUTH– SEIZURES– HYPEALGESIA/ALLODYNIA– TOLERANCE, PHYSICAL DEPENDENCE,ADDICTION
    • MANAGEMENT OF OPIOIDS SIDE EFFECTS38NALOXONEANTIEMETICSLAXATIVESANTICHOLINERGICSPSYCHOSTIMULANTSANTIPSYCHOTICSPOLYPHARMACY
    • NALOXONE (Narcan) Opioid Antagonist Used to reverse opioid-induced respiratorydepression May precipitate severe withdrawal symptoms andpain Onset of action 1-2 min Short duration of action- 45 min
    • NALOXONE DOSAGE RESPIRATORY DEPRESSION RR < 8/min DILUTE !!! 1 ml in 9 ml normal saline 0.04 mg IV push over 15 sec every 1-3 min PRN RESPIRATORY ARREST 1 ml UNDILUTED !!! = 0.4 mg IV push over 15 sec follow by 0.4 mg every 1- 3 min PRN
    • OPIOID naïve ADULTS Avoid starting long acting opioid !!! Start small doses short acting (Oxycodone 5 mg q3hprn, MSIR 15 mg q3h prn, Dilaudid 2mg q3h prn) Acute severe pain- Morphine 5-10 mg IV, Dilaudid0.5-2 mg IV, Toradol 15-30 mg IV IV-PCA- AVOID BASAL for first several hours and CAVEAT- Pts with respiratory disease, sleep apnea
    • IV –PCA Patient Controlled AnalgesiaIf pain is not controlled:3 choices- increase basal hourly rate- increase rescue doses- increase both (most common approach)Mild-moderate pain- increase dose by 25%Severe pain- increase dose by 50%Or increase basal rate based on # of rescues taken inthe last 12-24 hours
    • RESCUE-PRN dose IV rescue- ½ of IV hourly basal dose IV rescue can be given every 10- 15-20 min PO rescue- 10-20 % of TOTAL daily opioid dosegiven every 2-3 hours PRN
    • IV- PCA Do not prescribe rescue doses in delirious patients !!! Family members can not operate PCA ! CAB= Clinician activated bolus, given by nurse/MD.Used for pain crisis, prior to tests or PT Methadone and Fentanyl require separate IV line
    • SWITCH from FENTANYL PATCH toIV-PCA Determine target IV PCA setting Remove patches (in most cases) Start with 0 basal (in most cases) 6h after patch removal increase basal to 50% oftarget dose 12h after patch removal increase basal to full target
    • SWITCH from IV PCA to FENTANYL PATCH Determine patch dose 6h after patch placement decrease PCA basal by 50% 12h after patch placement D/C basal and continuerescues overnight D/C PCA in AM and start oral PRN rescues
    • OPIOIDS RESTRICTED to Pain Services atMSKCC Fentanyl PCA- for basal and rescues at and above 50mcg/h Dilaudid PCA- for basal and rescues at and above 0.4mg/h IV Methadone IV OxymorphoneMORPHINE PCA IS UNRESTRICTED!!!
    • TAPERING OF OPIOIDS Literature- Pts can tolerate 75% decrease withoutwithdrawal symptoms Clinical experience- many Pts need slow taper- 25-50% or less every 2-3 days Educate Pts on withdrawal symptoms and how tomanage it
    • PRINCIPLES OF PAIN MANAGEMENT- SUMMARY - Cancer pain can - and must be - treated Establish underlying diagnosis of pain Use analgesics AROUND THE CLOCK and PRN !!! WHO-3-step analgesic ladder approach, non-opioids and opioid mu- agonists Prophylactic bowel regimen Add adjuvant analgesics when indicated Continued supervision and dose adjustments
    • Thank You